AQST
Price:
$4.18
Market Cap:
$380.63M
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2018-07-25
Stock Exchange
NASDAQ
Ticker
AQST
According to Aquestive Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 36.59%. This represents a change of 177.85% compared to the average of 13.17% of the last 4 quarters.
The mean historical ROE of Aquestive Therapeutics, Inc. over the last ten years is 121.11%. The current 36.59% ROE has changed -69.79% with respect to the historical average. Over the past ten years (40 quarters), AQST's ROE was at its highest in in the March 2019 quarter at 243.16%. The ROE was at its lowest in in the December 2018 quarter at -138.33%.
Average
121.11%
Median
52.71%
Minimum
-608.89%
Maximum
1.19%
Discovering the peaks and valleys of Aquestive Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 1.19%
Minimum Annual Increase = -1903.93%
Minimum Annual ROE = -608.89%
Year | ROE | Change |
---|---|---|
2023 | 7.39% | -85.45% |
2022 | 50.78% | -53.68% |
2021 | 109.62% | -18.66% |
2020 | 134.78% | -88.64% |
2019 | 1.19% | -294.92% |
2018 | -608.89% | -1903.93% |
2017 | 33.75% | -38.22% |
The current ROE of Aquestive Therapeutics, Inc. (AQST) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
55.93%
5-year avg
297.88%
10-year avg
121.11%
Aquestive Therapeutics, Inc.’s ROE is greater than Evoke Pharma, Inc. (-964.02%), less than Adamis Pharmaceuticals Corporation (0.93%), greater than Guardion Health Sciences, Inc. (-71.26%), greater than AcelRx Pharmaceuticals, Inc. (-48.62%), less than Dynavax Technologies Corporation (2.76%), less than Amphastar Pharmaceuticals, Inc. (25.42%), less than Lantheus Holdings, Inc. (49.15%), less than ANI Pharmaceuticals, Inc. (6.02%), greater than Ironwood Pharmaceuticals, Inc. (-2.78%), less than Alkermes plc (22.66%), less than Eagle Pharmaceuticals, Inc. (4.41%), greater than Shuttle Pharmaceuticals Holdings, Inc. (-217.58%), greater than Mallinckrodt plc (-117.04%), less than Agile Therapeutics, Inc. (104.04%), less than Lifecore Biomedical, Inc. (26.37%), greater than Organogenesis Holdings Inc. (-2.77%), greater than Lucy Scientific Discovery Inc. (-377.80%), greater than Alimera Sciences, Inc. (-33.70%),
Company | ROE | Market cap |
---|---|---|
-964.02% | $3.17M | |
0.93% | $7.25M | |
-71.26% | $17.02M | |
-48.62% | $14.58M | |
2.76% | $1.45B | |
25.42% | $2.21B | |
49.15% | $7.08B | |
6.02% | $1.27B | |
-2.78% | $720.42M | |
22.66% | $4.42B | |
4.41% | $55.19M | |
-217.58% | $3.42M | |
-117.04% | $4.52M | |
104.04% | $10.43M | |
26.37% | $147.38M | |
-2.77% | $327.46M | |
-377.80% | $906.91K | |
-33.70% | $302.38M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aquestive Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aquestive Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Aquestive Therapeutics, Inc.'s ROE?
How is the ROE calculated for Aquestive Therapeutics, Inc. (AQST)?
What is the highest ROE for Aquestive Therapeutics, Inc. (AQST)?
What is the 3-year average ROE for Aquestive Therapeutics, Inc. (AQST)?
What is the 5-year average ROE for Aquestive Therapeutics, Inc. (AQST)?
How does the current ROE for Aquestive Therapeutics, Inc. (AQST) compare to its historical average?